一般演題（口演IS）3 IS口演3：International Session3

[IS-013] Phase 3 study（Study 309/KEYNOTE-775）of lenvatinib plus pembrolizumab vs treatment of physician's choice in advanced endometrial cancer：Japanese subset

オンデマンド配信

^○Mayu Yunokawa¹, Kan Yonemori², Kimio Ushijima³, Jun Sakata⁴, Ayumi Shikama⁵, Shinichiro Minobe⁶, Tomoka Usami⁷, Takayuki Enomoto⁸, Kazuhiro Takehara⁹, Kosei Hasegawa¹⁰, Wataru Yamagami¹¹, Keiko Yamamoto¹², Shirong Han¹², Lea Dutta¹³, Robert Orlowski¹⁴, Takuma Miura¹⁵, Vicky Makker¹⁶, Keiichi Fujiwara¹⁰ (1.Cancer Institute Hospital of JFCR, Tokyo, Japan, 2.National Cancer Center Hospital, Tokyo, Japan, 3.Kurume University Hospital, Fukuoka, Japan, 4.Aichi Cancer Center Hospital, Aichi, Japan, 5.University of Tsukuba Hospital, Ibaraki, Japan, 6.Hokkaido Cancer Center, Hokkaido, Japan, 7.Ehime University Hospital, Ehime, Japan, 8.Niigata University Medical ＆ Dental Hospital, Niigata, Japan, 9.National Hospital Organization Shikoku Cancer Center, Ehime, Japan, 10.Saitama Medical University International Medical Center, Saitama, Japan, 11.Keio University Hospital, Tokyo, Japan, 12.MSD K.K., Tokyo, Japan, 13.Eisai Inc., Woodcliff Lake, NJ, USA, 14.Merck ＆ Co., Inc., Kenilworth, NJ, USA, 15.Eisai Co., Ltd., Tokyo, Japan, 16.Memorial Sloan Kettering Cancer Center, New York, NY, USA)